ENOUGH

PUBLIC

Name	ENOUGH
Tagline	Makes protein sustainable by producing ABUNDA mycoprotein, made by fermenting fungi with natural sugars from grains.
Headquarters	Glasgow, Scotland
Founded	2015
Stage	Growth / Late Stage
Business Model	B2B
Industry	Cleantech / Climatetech
Technology	Biotech / Life Sciences
Geography	Western Europe
Growth Profile	Venture Scale
Founding Team	Academic Spinout
Funding Label	$100M+
Total Disclosed	$110.82M (estimated) [TheCompanyCheck]

Links

PUBLIC

• Website: https://www.enough-food.com/
• LinkedIn: https://uk.linkedin.com/company/enough-food

Executive Summary

PUBLIC ENOUGH operates as a B2B ingredient supplier, producing a sustainable mycoprotein called ABUNDA via fermentation, a model that positions it to scale within the food supply chain without the friction of consumer branding [Dealroom]. The company's ambition to produce one million tonnes of mycoprotein by 2032, backed by over $100 million in disclosed capital, frames it as a capital-intensive, infrastructure-driven bet on the future of protein [enough-food.com] [Sifted, 2023].

Founded in 2015 as a spin-out from the University of Strathclyde, the company benefits from the deep industry expertise of CEO Jim Laird, a former executive at Quorn, the established market leader in mycoprotein [Business Insider, August 2023]. Its core product, ABUNDA, is a neutral-flavored, high-fiber ingredient sold to food manufacturers for use in alternative meat, seafood, and dairy products, with confirmed partnerships extending to Unilever, Cargill, and European poultry processor Plukon [Green Queen] [cargill.com].

The business model is predicated on achieving low-cost production at scale, a path validated by the 2022 commissioning of a 10,000-tonne-per-annum facility in the Netherlands, with plans to double that capacity by early 2025 [foodmanufacture.co.uk, 2022-09-20] [foodnavigator.com, 2023-08-21]. Over the next 12-18 months, the key milestones to monitor are the successful ramp-up of the Dutch facility, the conversion of announced partnerships into sustained offtake agreements, and the company's ability to secure the additional capital required to progress toward its 2027 and 2032 capacity targets.

Data Accuracy: GREEN -- Confirmed by multiple independent sources including Dealroom, Business Insider, and industry trade publications.

Taxonomy Snapshot

Axis	Classification
Stage	Growth / Late Stage
Business Model	B2B
Industry / Vertical	Cleantech / Climatetech
Technology Type	Biotech / Life Sciences
Geography	Western Europe
Growth Profile	Venture Scale
Founding Team	Academic Spinout
Funding	$100M+ (total disclosed ~$110,820,000)

Company Overview

PUBLIC

The company began as a research project spun out of the University of Strathclyde in 2015, initially operating under the name 3F BIO [Sifted]. Its founding team, Jim Laird, Craig Johnston, and David Ritchie, emerged from the university's academic environment with a focus on fermentation technology [proteinproductiontechnology.com]. The central narrative of the company's early years is defined by this academic origin and the subsequent recruitment of Jim Laird, a former executive at the established mycoprotein company Quorn, to lead the commercial venture [Business Insider, August 2023].

Headquartered in Glasgow, Scotland, the company's key operational milestone was the establishment of its first large-scale production facility in Sas van Gent, the Netherlands. This site, which became operational in the fourth quarter of 2022, was built with an initial annual capacity of 10,000 tonnes [foodmanufacture.co.uk, 2022-09-20]. The facility's launch represented a critical transition from pilot-scale research to commercial production, a step funded by a $51 million Series B round closed in September 2021 [Green Queen, September 2021].

Subsequent scaling plans have been aggressive and public. Following a $43.5 million growth round in August 2023, the company announced intentions to double the Netherlands facility's capacity to 20,000 tonnes per annum by early 2025 [foodnavigator.com, 2023-08-21]. Longer-term ambitions are framed around specific tonnage targets: more than 50,000 tonnes of total capacity by 2027, and a vision to produce one million tonnes of its ABUNDA mycoprotein by 2032 [enough-food.com].

Data Accuracy: GREEN -- Founding details and key milestones corroborated by multiple independent sources including Sifted, Business Insider, and industry trade publications.

Product and Technology

MIXED ENOUGH's commercial offering is a single, high-volume ingredient: ABUNDA mycoprotein, a whole food protein produced via continuous fermentation of the fungi Fusarium venenatum. The company's public positioning centers on the ingredient's functional and environmental profile, which it sells to food manufacturers as a B2B component for meat, seafood, and dairy alternatives [enough-food.com].

The core technical process is a zero-waste fermentation that converts sugars from grains into a fibrous, protein-rich biomass [enough-food.com]. This process yields a product the company describes as neutral in taste and fibrous in texture, designed to mimic the mouthfeel of animal protein [enough-food.com]. ABUNDA is marketed as a complete protein, containing all nine essential amino acids, and is high in dietary fibre [Dealroom]. The underlying fungal strain is the same one used by the established brand Quorn, a point of both validation and potential commoditization risk [AgFunderNews].

Scaling this fermentation process is the central technological challenge, and ENOUGH's primary public milestone is the operational 10,000-tonne-per-annum facility in Sas van Gent, Netherlands, which came online in late 2022 [foodmanufacture.co.uk, September 2022]. The company has announced plans to double that capacity to 20,000 tonnes by early 2025 [FoodNavigator, August 2023]. The facility's ultimate potential is cited as 60,000 tonnes [AgFunderNews]. The company's long-term production targets are publicly ambitious: more than 50,000 tonnes of capacity by 2027 and a vision to produce one million tonnes by 2032 [enough-food.com].

Data Accuracy: GREEN -- Product claims and production milestones are consistently reported across the company website and multiple trade publications.

Market Research

PUBLIC The market for sustainable protein is no longer a niche concern but a structural response to the dual pressures of climate change and global food security, a shift that has moved alternative proteins from the periphery to the core of food system investment.

Third-party sizing for the specific mycoprotein segment is limited, but one projection places the global mycoprotein market at approximately $761.8 million in 2025, growing at a 6.2% compound annual rate [futuremarketinsights.com]. This figure, while modest, represents a defined sub-segment within the broader alternative protein landscape, which is measured in the tens of billions. For context, the global plant-based meat market alone was valued at $8.1 billion in 2023 and is projected to reach $23.4 billion by 2033, according to a separate report from Future Market Insights (analogous market, source). The mycoprotein segment's growth is underpinned by its unique position as a fermented, whole-food ingredient, distinct from plant-based isolates or cultivated meat.

Demand is being pulled by three primary forces. First, consumer awareness of the environmental footprint of animal agriculture is rising, with life-cycle assessments showing products like ABUNDA mycoprotein can reduce land, water, and carbon impacts by over 90% compared to beef [enough-food.com]. Second, major food manufacturers and retailers are under public pressure to decarbonize their supply chains and meet Scope 3 emissions targets, creating a direct B2B sales channel for sustainable ingredients. Third, regulatory frameworks in Europe and North America are increasingly supportive of novel food ingredients that can demonstrably improve sustainability, though the approval pathway remains a gating factor for new entrants.

The competitive landscape for consumer stomach-share is broad, but ENOUGH's B2B model positions it against other ingredient suppliers rather than consumer brands. Key adjacent markets include plant-based protein concentrates (e.g., pea, soy), precision fermentation-derived proteins (e.g., whey, egg white), and other biomass fermentation companies producing mycelium. The primary substitute market remains conventional animal protein, a multi-trillion-dollar industry where even a single-digit share shift represents a massive opportunity. A critical macro force is the volatility and projected long-term rise in commodity feed prices for livestock; fermentation processes that utilize stable, plant-based sugar feedstocks can offer a more predictable and potentially lower-cost protein production model over time.

Mycoprotein Market 2025 | 761.8 | $M
Plant-Based Meat Market 2023 | 8100 | $M
Plant-Based Meat Market 2033 | 23400 | $M

The sizing data illustrates the gap between the established, multi-billion-dollar plant-based category and the more specialized mycoprotein segment ENOUGH operates within. For investors, the bet is not on capturing the existing mycoprotein market but on enabling its expansion into a much larger portion of the alternative protein space through cost and scale advantages.

Data Accuracy: YELLOW -- Mycoprotein market size from a single third-party report; broader plant-based market figures are analogous and used for context.

Competitive Landscape

MIXED ENOUGH operates in a crowded field of alternative protein producers, but its B2B ingredient model and focus on large-scale fermentation of a known mycoprotein strain carve out a distinct lane. The competitive map is defined by technology type, go-to-market strategy, and stage of commercial scale.

Company	Positioning	Stage / Funding	Notable Differentiator	Source
ENOUGH	B2B mycoprotein ingredient supplier via fermentation.	Growth / Late Stage; $110.82M+ raised.	Focus on cost and scale for CPG partners; uses established Fusarium venenatum strain.	[Dealroom]; [enough-food.com]
Quorn	Vertically integrated, branded consumer mycoprotein products.	Mature, owned by Monde Nissin.	First-mover with decades of consumer brand recognition and retail distribution.	[Wikipedia]
Nature's Fynd	B2B & B2C producer of Fy protein via fermentation of a novel microbe.	Growth stage; $500M+ raised.	Proprietary microbial strain from Yellowstone; produces whole protein with fats.	[Crunchbase]
Meati	Branded consumer cuts of mycelium-based meat alternatives.	Growth stage; $275M+ raised.	Focus on whole-muscle cuts (steak, chicken) and D2C/retail branding.	[Crunchbase]
The Protein Brewery	B2B fermented protein ingredient (Fermotein) from fungi.	Growth stage; €22M Series B (2021).	Uses a different fungal strain and process; targets ingredient market like ENOUGH.	[Dealroom]

The competitive landscape breaks into three primary segments. First, the incumbent is Quorn, which pioneered mycoprotein for human consumption and remains the category-defining consumer brand. Quorn's advantage is its locked-in retail shelf space and decades of consumer trust, but its model is vertically integrated, producing finished goods rather than supplying ingredients to others. Second, the challengers are other fermentation-focused companies like Nature's Fynd, Meati, and The Protein Brewery. These firms compete for similar investor capital and partnership deals, but their technological approaches and end-market focuses differ. Nature's Fynd uses a novel extremophile microbe, while Meati focuses on textured whole cuts for consumers. The Protein Brewery is the most direct comparator as another B2B fungal ingredient play. Third, adjacent substitutes include plant-based protein concentrate producers (e.g., pea protein giants) and cultivated meat companies, though these address different parts of the cost, scalability, and regulatory spectrum.

ENOUGH's defensible edge today rests on two pillars: capital-efficient scale and partner validation. The company's leadership, particularly CEO Jim Laird's prior experience scaling Quorn's fermentation, provides rare operational knowledge in a capital-intensive field [Business Insider, August 2023]. This talent edge is perishable if key personnel depart, but the operational playbook is now embedded in its Sas van Gent facility. More concretely, ENOUGH's partnerships with established giants like Cargill, Unilever, and Plukon Food Group serve as validation and create a distribution moat [Cargill]; [Green Queen]. These are multi-year development and supply agreements that competitors cannot easily replicate overnight. The edge is durable if ENOUGH consistently meets quality, volume, and cost targets, building switching costs for its partners.

The company is most exposed on two fronts. Technologically, its use of the same Fusarium venenatum strain as Quorn is a double-edged sword. It de-risks regulatory approval and consumer acceptance but opens the door to intellectual property challenges and limits its marketing claim to true novelty. A competitor with a superior novel strain that offers better nutrition or functionality could leapfrog it. Commercially, ENOUGH is vulnerable to pricing pressure from large-scale plant protein producers (e.g., pea, soy) if it cannot drive its cost per tonne low enough to be competitive as a bulk ingredient. Its model also does not own the consumer relationship, capping its margin potential and brand value creation compared to a branded player like Meati.

The most plausible 18-month scenario involves a shakeout among B2B fermentation ingredient suppliers, where the winner secures a landmark contract with a global fast-food chain or CPG conglomerate for a flagship product launch. In this scenario, ENOUGH could be the winner if its Netherlands facility successfully doubles capacity on schedule and delivers consistent quality to its existing partners, prompting a follow-on order from Cargill or Unilever. The loser would be a competitor that fails to move from pilot to commercial scale, or whose ingredient requires costly and time-consuming novel food approvals in key markets like the EU or US, stalling partnership momentum.

Data Accuracy: GREEN -- Confirmed by multiple public sources including company website, Dealroom, and press coverage of competitors.

Opportunity

PUBLIC The prize for ENOUGH is a position as a foundational, high-volume ingredient supplier in a global protein market where sustainability and cost are becoming non-negotiable constraints for major food producers.

The headline opportunity is to become the primary, scaled supplier of mycoprotein to the global food industry, analogous to how ADM or Cargill supply commodity ingredients today, but for the alternative protein transition. This outcome is reachable not as a branded consumer play but as a B2B infrastructure layer. The evidence lies in the company's established path to industrial scale and its early anchor partnerships. Its flagship facility in Sas van Gent, the Netherlands, is operational with a 10,000-tonne annual capacity and plans to double that by early 2025 [foodnavigator.com, August 2023]. The site's ultimate potential is 60,000 tonnes [agfundernews.com], providing a clear, asset-backed roadmap. Critically, this capacity is already spoken for by major offtakers: Unilever will test ABUNDA in its The Vegetarian Butcher line, Cargill is co-creating products with it, and Plukon Food Group is using it for chicken analogues [greenqueen.com.hk]. This combination of built capacity and committed demand from industry titans moves the opportunity from aspiration to execution.

Growth scenarios outline specific paths to that headline outcome. Each depends on a different catalyst tied to the company's current partnerships and market positioning.

Scenario	What happens	Catalyst	Why it's plausible
CPG Ingredient Standard	ABUNDA becomes the default mycoprotein in reformulated products from large, diversified consumer packaged goods companies.	A successful, large-scale product launch with Unilever's The Vegetarian Butcher line, proving performance and consumer acceptance in a flagship brand.	Unilever has publicly committed to testing ABUNDA, providing a direct route to mass-market shelves [greenqueen.com.hk]. The company's CEO is a former Quorn executive, bringing deep experience in scaling mycoprotein within a major CPG context [Business Insider, August 2023].
Industrial Protein Partner	ENOUGH evolves into a joint-development partner for meat and poultry processors seeking to blend or replace animal protein.	The partnership with Plukon Food Group, a major European poultry processor, leads to a commercially successful hybrid or fully alternative product line.	Plukon is already using ABUNDA for chicken and meat analogues, indicating a move beyond niche plant-based brands to core animal protein producers [greenqueen.com.hk]. This validates the ingredient's functional parity in industrial meat applications.
Platform for Foodservice	ABUNDA becomes the cost-effective, sustainable protein base for quick-service restaurant chains and prepared food manufacturers.	A national rollout with a fast-food chain or a major foodservice distributor, driven by the ingredient's neutral flavor and promised cost advantages at scale.	The company's B2B model and focus on cost and scale are explicitly aimed at serving large foodservice brands [Dealroom]. Products are already noted as going into "supermarkets and fast food chains" [Sifted].

What compounding looks like is a classic industrial scaling flywheel. Initial anchor partnerships (Unilever, Cargill, Plukon) provide the demand certainty to justify capital expenditure on larger fermentation capacity. Increased volume drives down the unit cost of production through operational use, making ABUNDA more competitive against both animal protein and other alternative proteins. Lower cost and proven supply attract the next tier of large manufacturers, generating more demand to fill the next capacity expansion. The company's published environmental metrics,97% less feed and 99% less water than red meat [enough-food.com],become a stronger commercial lever as carbon and water pricing regimes advance, further tilting the economics in favor of its process. The flywheel is already in motion, evidenced by the plan to double capacity within two years of the first plant's operation, a decision likely underpinned by offtake agreements.

The size of the win, in a bullish scenario, can be framed against a public peer. Quorn Foods, the consumer-facing mycoprotein pioneer, was acquired by Monde Nissin Corporation for approximately £550 million (about $700 million) in 2015. ENOUGH's ambition is fundamentally different,it aims to be the ingredient supplier, not the brand,but the comparison is instructive on category value. If ENOUGH executes on its capacity roadmap and captures a material share of the B2B mycoprotein market, a valuation anchored to production volume and contracted revenue becomes plausible. The company's own vision is to produce 1,000,000 tonnes of mycoprotein by 2032 [enough-food.com]. Even at a conservative estimated revenue per tonne, achieving a fraction of that goal would support a venture-scale outcome. This is a scenario, not a forecast, but it illustrates the magnitude of the opportunity if the company can translate its technological and partnership head start into durable industrial scale.

Data Accuracy: GREEN -- Capacity plans, partnership details, and funding rounds are corroborated by multiple industry publications and company sources.

Sources

PUBLIC

1. [Dealroom] ENOUGH (formerly 3F BIO) | https://app.dealroom.co/companies/enough

2. [enough-food.com] ENOUGH - delicious, nutritious, sustainable | https://www.enough-food.com/

3. [Sifted, 2023] ENOUGH: The Scottish startup that raised €40M for alternative meat | https://sifted.eu/articles/scottish-startup-enough-40m-for-alternative-meat-news

4. [Business Insider, August 2023] Fungi-based meat alternative startup Enough, founded by a former Quorn boss, just raised $43.5 million with this 16-slide pitch deck | https://www.businessinsider.com/enough-fungi-based-meat-alternative-startup-raises-435-million-2023-8

5. [Green Queen] Vegan Protein Startup ENOUGH US$51M Series B | https://www.greenqueen.com.hk/vegan-protein-startup-enough-us51m-series-b/

6. [proteinproductiontechnology.com] ENOUGH | https://www.proteinproductiontechnology.com/news/enough

7. [foodmanufacture.co.uk, September 2022] Enough opens first large-scale mycoprotein plant in the Netherlands | https://www.foodmanufacture.co.uk/Article/2022/09/20/enough-opens-first-large-scale-mycoprotein-plant-in-the-netherlands

8. [foodnavigator.com, August 2023] Enough to double mycoprotein production capacity after €40m funding round | https://www.foodnavigator.com/Article/2023/08/21/enough-to-double-mycoprotein-production-capacity-after-40m-funding-round

9. [AgFunderNews] ENOUGH raises €40M to scale mycoprotein production in the Netherlands | https://agfundernews.com/enough-raises-e40m-to-scale-mycoprotein-production-in-the-netherlands

10. [futuremarketinsights.com] Mycoprotein Market Outlook (2025-2035) | https://www.futuremarketinsights.com/reports/mycoprotein-market

11. [Wikipedia] Quorn | https://en.wikipedia.org/wiki/Quorn

12. [Crunchbase] Nature's Fynd | https://www.crunchbase.com/organization/nature-s-fynd

13. [Crunchbase] Meati | https://www.crunchbase.com/organization/meati

14. [Cargill] Cargill partners with ENOUGH to expand alternative protein options with innovative mycoprotein | https://www.cargill.com/2023/cargill-partners-with-enough-to-expand-alternative-protein-options

15. [TheCompanyCheck] ENOUGH | https://www.thecompanycheck.com/company/b/enough/k81g02j1vgi664l1v

16. [Green Queen, September 2021] Vegan Protein Startup ENOUGH US$51M Series B | https://www.greenqueen.com.hk/vegan-protein-startup-enough-us51m-series-b/